Mereo Biopharma Group Plc(MREO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MREO Mereo Biopharma Group Plc

Trading 08-27 12:44:16 EDT

0.2754

-0.0026

-0.94%

High0.2881	Low0.2750	Vol778.37K
Open0.2880	D1 Closing0.2780	Amplitude4.71%
Mkt Cap43.82M	Tradable Cap36.08M	Total Shares159.13M
T/O216.79K	T/O Rate0.59%	Tradable Shares131.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MREO","market":"US","secType":"STK","nameCN":"Mereo Biopharma Group Plc","latestPrice":0.2754,"timestamp":1787849048609,"preClose":0.278,"halted":0,"volume":778370,"delay":0,"changeRate":-0.009352517985611679,"floatShares":131000000,"shares":159131700,"eps":-0.1753,"marketStatus":"Trading","change":-0.0026,"latestTime":"08-27 12:44:16 EDT","open":0.288,"high":0.2881,"low":0.275,"amount":216785.0118224,"amplitude":0.047122,"askPrice":0.2758,"askSize":100,"bidPrice":0.275,"bidSize":300,"shortable":3,"etf":0,"ttmEps":-0.1753,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787860800000},"marketStatusCode":2,"adr":0,"adrRate":5,"listingDate":1556078400000,"exchange":"NASDAQ","adjPreClose":0.278,"preHourTrading":{"tag":"盘前","latestPrice":0.2823,"preClose":0.278,"latestTime":"09:26 EDT","volume":11911,"amount":3363.53025727,"timestamp":1787837197990,"change":0.0043,"changeRate":0.015468,"amplitude":0.05},"postHourTrading":{"tag":"盘后","latestPrice":0.2822,"preClose":0.278,"latestTime":"19:56 EDT","volume":70358,"amount":19395.21601,"timestamp":1787788585686,"change":0.0042,"changeRate":0.015108,"amplitude":0.045683},"volumeRatio":1.753092,"impliedVol":1.7784,"impliedVolPercentile":0.8008},"requestUrl":"/m/hq/s/MREO/wiki","defaultTab":"wiki","newsList":[{"id":"2662748238","title":"European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2662748238","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662748238?lang=en_us&edition=fundamental","pubTime":"2026-08-26 23:13","pubTimestamp":1787757227,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were tracking lower late Wednesday morning, declining 0.46% to 1,977.10 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by accommodations booking site trivago  and biopharmaceutical company argenx , which advanced 2.9% and 2.6% respectively. They were followed by semiconductor company Sequans Communications  and 3D printer company Materialise , which rose 2% and 1.2% respectively.The decliners from continental Europe were led by biopharmaceutical company DBV Technologies  and software firm SAP , which fell 3.5% and 2.7% respectively. They were followed by telecommunications company Ericsson  and pharmaceutical company Novo Nordisk , which lost 2.1% and 1.8% respectively.The gainers from the UK were led by biopharmaceutical companies Amarin  and Akari Therapeutics , which climbed 7.1% and 2.9% respectively. They were followed by tobacco company British American Tobacco  and biopharmaceuti","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BZ1G4Q59.USD","DAVA","IE0034235188.USD","LU1093756325.SGD","TRVG","BK4141","SQNS","PRNT","AMRN","BK4023","LU0154236417.USD","AUTL","LU2324357040.USD","BK4546","BK4075","BK4020","IE00B2B36J28.USD","BK4554","LU0109394709.USD","BK4532","IE00BJT1NW94.SGD","BTI","LU0823416689.USD","ERIC","MTLS","BK4139","ARGX","NICO","IE0009355771.USD","BK4505","LU0072461881.USD","LU0889565916.HKD","NVOC","THNR","NVO","LU2543165471.USD","LU1983260115.SGD","BK4007","BK4613","BK4585","BDRX","NVOH","BK4134","NVOX","OZEM","IBB","IE00BKVL7J92.USD","TBXU","LU0320765992.SGD","LU0648005311.SGD","IE0002141913.USD","IE00BJJMRZ35.SGD","BK4077","PPH","BK4588","LU0006061336.USD","SAP","BK4515","BK4528","DBVT","LU0084288595.USD","LU1093756168.USD","LU0162691827.USD","BCYC","FMED","AKTX","BK4599","IE00B4R5TH58.HKD","MREO","BK4591","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660060784","title":"Viridis puts huge US$1.86B value on Brazilian rare earths play","url":"https://stock-news.laohu8.com/highlight/detail?id=2660060784","media":"The West Australian","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660060784?lang=en_us&edition=fundamental","pubTime":"2026-08-20 06:31","pubTimestamp":1787178662,"startTime":"0","endTime":"0","summary":"Viridis Mining & Minerals’ DFS has valued its Colossus rare earth project in Brazil at US$1.86B. The mine is forecast to pump out a whopping US$5.97B in EBITDA over a 25-year mine life from revenue of US$8.54B.","market":"hk","thumbnail":"https://images.thewest.com.au/publication/C-22753804/8a7f9be80d2bb22dcdba79882fe15cca7be0aa78.jpg","type":0,"news_type":0,"thumbnails":["https://images.thewest.com.au/publication/C-22753804/8a7f9be80d2bb22dcdba79882fe15cca7be0aa78.jpg"],"rights":{"source":"thewest_stock","url":"https://thewest.com.au/business/bulls-n-bears/viridis-puts-huge-us186b-value-on-brazilian-rare-earths-play-c-22753804","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thewest.com.au/business/bulls-n-bears/viridis-puts-huge-us186b-value-on-brazilian-rare-earths-play-c-22753804","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thewest_stock","symbols":["BK4588","LU1791807156.HKD","BK4139","MVPS","BK4505","FXZ","LU2360107671.USD","MREO","LU1861220207.SGD","LU0106831901.USD","IRR","REMX","DFS","CRIT","LU1861217088.USD","BK4166","NPV","TREO","BK4585","LU1668664300.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660774440","title":"Mereo BioPharma Gets NASDAQ Extension to Regain $1 Minimum Bid Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2660774440","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660774440?lang=en_us&edition=fundamental","pubTime":"2026-08-19 19:54","pubTimestamp":1787140443,"startTime":"0","endTime":"0","summary":"Mereo BioPharma gets Nasdaq extension to regain $1 minimum bid complianceMereo BioPharma received a Nasdaq notice extending its deadline to regain the $1 minimum bid-price requirement to Feb. 16, 2027","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDLbKZJhz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MREO","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660419321","title":"Mereo Biopharma Group Plc : JP Morgan Cuts to Underweight from Neutral","url":"https://stock-news.laohu8.com/highlight/detail?id=2660419321","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660419321?lang=en_us&edition=fundamental","pubTime":"2026-08-19 10:45","pubTimestamp":1787107542,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nFWN44F0RF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MREO","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660959154","title":"European Equities Traded in the US as American Depositary Receipts Head Lower in Tuesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2660959154","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660959154?lang=en_us&edition=fundamental","pubTime":"2026-08-18 23:13","pubTimestamp":1787066007,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were trending lower in late Tuesday morning trading, declining 0.50% to 1,960.50 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by software firm SAP  and pharmaceutical company Sanofi , which increased 1.7% and 1.6% respectively. They were followed by healthcare tech company Royal Philips  and biopharmaceutical company DBV Technologies , which were up 1.5% and 1.3% respectively.The decliners from continental Europe were led by telecommunications company Nokia  and biopharmaceutical company Cellectis , which lost 3.8% and 2.9% respectively. They were followed by biotech firm Evaxion  and furniture maker Natuzzi , which dropped 1.6% and 1.5% respectively.The gainers from the UK were led by software firm Endava  and communications company WPP , which advanced 4.1% and 2.6% respectively. They were followed by pharmaceutical company AstraZeneca  and biotech company Trinity Biotech , which ro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0320765992.SGD","BK4568","BCS","DBVT","WPP","AFG","EPV","LU0432979614.USD","SLN","AZN","BK4505","PHG","BK4139","LU2237443382.USD","MREO","LU0006061336.USD","TRIB","LNOK","LU0058720904.USD","LU0128525929.USD","BK4528","BK4007","LU0648005311.SGD","NTZ","SAP","AZNH","BK4117","BK4023","CLLS","LU2237443549.SGD","LU2237443895.HKD","SNY","LU0708994859.HKD","BK4547","LU0029864427.USD","NOK","DAVA.AU","BK4588","DAVA","WPP.AU","BK4521","LU2237443978.SGD","BK4009","EVAX","IEUR","LU2462157665.USD","AKTX","LU2468319806.SGD","LU2089984988.USD","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660323436","title":"European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2660323436","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660323436?lang=en_us&edition=fundamental","pubTime":"2026-08-17 23:12","pubTimestamp":1786979555,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts started the week tracking modestly higher late Monday morning, rising 0.31% to 1,970.56 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical companies argenx  and DBV Technologies , which climbed 16% and 5.1% respectively. They were followed by telecommunications company Nokia  and biopharmaceutical company Cellectis , which advanced 2.5% and 2% respectively.The decliners from continental Europe were led by medical device maker EDAP TMS  and internet browser company Opera , which dropped 4.6% and 2.7% respectively. They were followed by brewing company Anheuser-Busch InBev  and consumer goods company Unilever , which lost 2.4% and 1.6% respectively.The gainers from the UK were led by biotech firm Autolus Therapeutics  and biopharmaceutical company Akari Therapeutics , which rose 6.3% and 2.8% respectively. They were followed by biopharmaceutical companies GSK  and Bicycle","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BUD","BK4592","NOK","BK4139","AFG","IE00BMPRXN33.USD","BK4505","GSK","IBB","LU0889565916.HKD","BK4007","WPP","UL","IEUR","LU0006061336.USD","LFGY","IE00BFTCPJ56.SGD","TBXU","DEO","BK4532","FOCL","IE0002141913.USD","FMED","EPV","AKTX","LU1983260115.SGD","DBVT","BCYC","LU0823416689.USD","ARGX","CLLS","AUTL","GSK.UK","LNOK","BK4169","MREO","OPRA","GSKH","IE00BJJMRZ35.SGD","BK4107","IE00B4R5TH58.HKD","DGE.UK","ULVR.UK","NCNA","BK4588","UN","WPP.AU","BK4009","BUD.AU","BK4117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660826694","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Achieve Life Sciences (ACHV), Mereo Biopharma Group Plc (MREO) and Demant (OtherWILLF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660826694","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660826694?lang=en_us&edition=fundamental","pubTime":"2026-08-17 19:40","pubTimestamp":1786966813,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Achieve Life Sciences (ACHV), Mereo Biopharma Group Plc (MREO) an...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-achieve-life-sciences-achv-mereo-biopharma-group-plc-mreo-and-demant-otherwillf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-achieve-life-sciences-achv-mereo-biopharma-group-plc-mreo-and-demant-otherwillf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","BK4139","LU0029874061.USD","XLV","ACHV","BK4137","HCSG","MREO","LU0128526141.USD","BK4585","LABU","XBI","BK4588","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659219198","title":"UK's Akari Therapeutics Q2 Net Loss Widens on Higher R&D for AKTX-101","url":"https://stock-news.laohu8.com/highlight/detail?id=2659219198","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659219198?lang=en_us&edition=fundamental","pubTime":"2026-08-14 05:33","pubTimestamp":1786656795,"startTime":"0","endTime":"0","summary":"UK's Akari Therapeutics Q2 net loss widens on higher R&D for AKTX-101OverviewUK-US oncology biotech's Q2 net loss widened yr/yr as R&D spending increasedCompany raised $8.6 mln in financing during Q2,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A1AY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","BK4148","MREO","AKTX","AKTS","BK4007","ADCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659165530","title":"European Equities Traded in the US Rise in Thursday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2659165530","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659165530?lang=en_us&edition=fundamental","pubTime":"2026-08-13 23:14","pubTimestamp":1786634079,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were higher late Thursday morning, rising 0.45% to 1,969.72 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical company Cellectis  and biotech firm Evaxion , which rose 4.9% and 2.9% respectively. They were followed by telecommunications company Nokia  and healthcare tech company Royal Philips , which increased 2.8% and 1.9% respectively.The decliners from continental Europe were led by Ascendis Pharma  and petroleum refiner Equinor , which fell 3.8% and 2.8% respectively. They were followed by oil and gas company Eni  and pharmaceutical company Novo Nordisk , which were down 1.8% and 0.7% respectively.The gainers from the UK were led by Autolus Therapeutics  and Silence Therapeutics , which rose 4.7% and 3.6% respectively. They were followed by software firm Endava  and British American Tobacco , which were up 3.3% and 2.9% respectively.The decliners from the UK and Ire","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["COAL","NICO","NOK","EVAX","LNOK","LU0300736062.USD","LU0889565916.HKD","IE00BMPRXN33.USD","LU1093756168.USD","E","NVOH","LU0300736492.USD","BK4020","MEDI","LU0162691827.USD","BK4007","BK4585","BK4139","IE00BMPRXR70.SGD","LU0648005311.SGD","LU1093756325.SGD","THNR","CLLS","ASND","BK4505","BK4075","BK4532","DAVA","LU0006061336.USD","LU0154236417.USD","BK4082","BK4134","NVO","BK4168","BK4588","BPH","SLX","OZEM","EQNR","BTI","NVOX","SLN","BK4599","LU1162221912.USD","LU1829250122.USD","LU0072461881.USD","BK4201","LU2543165471.USD","LU0320765646.SGD","MREO","PHG","IE00BKVL7J92.USD","BK4547","PPH","LU0084288595.USD","TRIB","BHP","LU0109394709.USD","AUTL","BP","IE00BZ1G4Q59.USD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658971522","title":"Switzerland's Pharvaris Q2 Loss Narrows, Cash Rises to €318 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2658971522","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658971522?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:02","pubTimestamp":1786532528,"startTime":"0","endTime":"0","summary":"Switzerland's Pharvaris Q2 loss narrows, cash rises to 318 mlnOverviewSwitzerland biopharma firm reported Q2 loss per share of 0.70, improving from prior yearCash and equivalents rose to 318 mln, with","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL1N4490CZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","MREO","MAZE","BK4007","BK4139","PHVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658973500","title":"Mereo BioPharma Group Price Target Maintained with a $1.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2658973500","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658973500?lang=en_us&edition=fundamental","pubTime":"2026-08-12 17:27","pubTimestamp":1786526820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MREO/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","MREO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658949348","title":"Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO) and Inhibikase Therapeutics (IKT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658949348","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658949348?lang=en_us&edition=fundamental","pubTime":"2026-08-12 05:50","pubTimestamp":1786485007,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Mereo Biopharma Group Plc (MREO) and Inhibikase Th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-mereo-biopharma-group-plc-mreo-and-inhibikase-therapeutics-ikt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-mereo-biopharma-group-plc-mreo-and-inhibikase-therapeutics-ikt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","LABU","BK4505","IKT","BK4588","HCSG","BK4581","MREO","XBI","BK4585","LU0029874061.USD","BK4137","BK4139","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658119769","title":"European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2658119769","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658119769?lang=en_us&edition=fundamental","pubTime":"2026-08-11 23:26","pubTimestamp":1786461976,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were tracking higher late Tuesday morning, rising 0.46% to 1,966.35 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical company Cellectis  and semiconductor company Sequans Communications , which advanced 4.7% and 2.6% respectively. They were followed by telecommunications company Nokia  and medical device maker EDAP TMS , which increased 3.2% and 1.3% respectively.The decliners from continental Europe were led by brewing company Anheuser-Busch InBev  and biopharmaceutical company DBV Technologies , which dropped 3.1% and 1% respectively. They were followed by consumer goods company Unilever  and pharmaceutical company Novo Nordisk , which were off 0.9% and 1% respectively.The gainers from the UK were led by biopharmaceutical company Mereo BioPharma Group  and biotech firm Autolus Therapeutics , which surged 27% and 8% respectively. They were followed by biotech company ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4505","AUTL","BK4007","DBVT","LU0006061336.USD","MREO","DGE.UK","NVOX","IE00BMPRXN33.USD","BK4169","TRIB","LU0689626769.HKD","DEO","UN","BK4020","IE00BKVL7J92.USD","PUK","BK4532","NVOH","BK4588","BK4559","BK4082","BUD","LU0154236417.USD","BK4158","AKTX","LU1093756168.USD","UL","BK4183","LU1093756325.SGD","SQNS","BK4599","CLLS","ULVR.UK","OZEM","BK4139","IE00BMPRXR70.SGD","PPH","02378","LU0124676726.USD","THNR","BK4585","BK4141","LNOK","BK4592","BK4162","BK4547","NOK","NVO","FOCL","IE00BZ1G4Q59.USD","SLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658191549","title":"Vor Biopharma Posts Wider-than-Expected Q2 Loss on Increased G&A Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2658191549","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658191549?lang=en_us&edition=fundamental","pubTime":"2026-08-11 21:42","pubTimestamp":1786455769,"startTime":"0","endTime":"0","summary":"Vor Biopharma posts wider-than-expected Q2 loss on increased G&A costsOverviewUS biotech firm's Q2 net loss widened, missing analyst expectationsR&D expenses dropped sharply yr/yr due to prior licensi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL1N4480KQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTX","VOR","BK4505","BK4139","MREO","ACHV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658153399","title":"Sentynl Therapeutics and Mereo Biopharma Announce Option and License Agreement for Alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2658153399","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658153399?lang=en_us&edition=fundamental","pubTime":"2026-08-11 21:25","pubTimestamp":1786454758,"startTime":"0","endTime":"0","summary":"Aug 11 (Reuters) - Mereo Biopharma Group PLC::*SENTYNL THERAPEUTICS AND MEREO BIOPHARMA ANNOUNCE OPTION AND LICENSE AGREEMENT FOR ALVELESTAT IN ALPHA-1 ANTITRYPSIN DEFICIENCY-ASSOCIATED LUNG DISEASE (","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nRSD3Kx8hP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","MREO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658246918","title":"Mereo BioPharma Group PLC Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2658246918","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658246918?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:52","pubTimestamp":1786452759,"startTime":"0","endTime":"0","summary":"Mereo BioPharma Group PLC reports results for the quarter ended June 30 - Earnings SummaryMereo BioPharma Group PLCMREO.OQreported a quarterly adjusted loss of 1 cent per share for the quarter ended J","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL8N44816L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","MREO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658065990","title":"Mereo BioPharma Q2 Operating Income USD -7.03 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658065990","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658065990?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:29","pubTimestamp":1786451372,"startTime":"0","endTime":"0","summary":"Aug 11 (Reuters) - Mereo BioPharma Q2 pretax profit USD -7.005 million.:((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))Source Date/Time = 11-AUG-202612:16:52.8 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nRSD3XQcFF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","MREO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658990034","title":"UK's Mereo BioPharma Q2 Loss Narrows on Lower R&D Spending","url":"https://stock-news.laohu8.com/highlight/detail?id=2658990034","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658990034?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:28","pubTimestamp":1786451330,"startTime":"0","endTime":"0","summary":"UK's Mereo BioPharma Q2 loss narrows on lower R&D spendingOverviewUK rare disease drug developer's Q2 net loss narrowed yr/yr due to lower R&D and G&A expensesCompany entered option and license agreem","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL1N4480H4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","RARE","BK4082","BK4139","GUTS","MREO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658990481","title":"Mereo BioPharma Group Q2 EPS $(0.01), Inline","url":"https://stock-news.laohu8.com/highlight/detail?id=2658990481","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658990481?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:17","pubTimestamp":1786450623,"startTime":"0","endTime":"0","summary":"Mereo BioPharma Group (NASDAQ:MREO) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. This is a 50 percent increase over losses of $(0.02) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61105953/mereo-biopharma-group-q2-eps-0-01-inline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MREO","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658990409","title":"Press Release: Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2658990409","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658990409?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:15","pubTimestamp":1786450500,"startTime":"0","endTime":"0","summary":"significance against the primary endpoints of reduction in annualized. clinical fracture rate, however, both achieved high statistical. significance against the key secondary endpoint of improvement in bone. mineral density, as well as reductions in vertebral fractures and. improvements in patient reported outcomes  associated with disease. severity, pain / discomfort and daily activities, with these PRO. improvements achieving statistical significance in the Orbit study.Setrusumab also achieved meaningful reductions in fractures in certain. bones and in patients with higher fracture frequencies. Both studies","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4126","BK4139","MREO","OI"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mereobiopharma.com","stockEarnings":[{"period":"1week","weight":-0.1075},{"period":"1month","weight":-0.0798},{"period":"3month","weight":-0.1942},{"period":"6month","weight":-0.2499},{"period":"1year","weight":-0.842},{"period":"ytd","weight":-0.3329}],"compareEarnings":[{"period":"1week","weight":-0.0039},{"period":"1month","weight":0.0365},{"period":"3month","weight":0.0152},{"period":"6month","weight":0.1168},{"period":"1year","weight":0.1874},{"period":"ytd","weight":0.1234}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.015037},{"month":2,"riseRate":0.428571,"avgChangeRate":0.010455},{"month":3,"riseRate":0,"avgChangeRate":-0.168155},{"month":4,"riseRate":0.571429,"avgChangeRate":0.09425},{"month":5,"riseRate":0.25,"avgChangeRate":-0.070465},{"month":6,"riseRate":0.625,"avgChangeRate":0.340287},{"month":7,"riseRate":0.625,"avgChangeRate":-0.038517},{"month":8,"riseRate":0.75,"avgChangeRate":0.068286},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.100596},{"month":10,"riseRate":0.428571,"avgChangeRate":0.068788},{"month":11,"riseRate":0.285714,"avgChangeRate":-0.101401},{"month":12,"riseRate":0.428571,"avgChangeRate":0.001557}],"exchange":"NASDAQ","name":"Mereo Biopharma Group Plc","nameEN":"Mereo Biopharma Group Plc","securityTypeName":"DR","adrRate":"1:5"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mereo Biopharma Group Plc(MREO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mereo Biopharma Group Plc(MREO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mereo Biopharma Group Plc,MREO,Mereo Biopharma Group Plc股票,Mereo Biopharma Group Plc股票老虎,Mereo Biopharma Group Plc股票老虎国际,Mereo Biopharma Group Plc行情,Mereo Biopharma Group Plc股票行情,Mereo Biopharma Group Plc股价,Mereo Biopharma Group Plc股市,Mereo Biopharma Group Plc股票价格,Mereo Biopharma Group Plc股票交易,Mereo Biopharma Group Plc股票购买,Mereo Biopharma Group Plc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mereo Biopharma Group Plc(MREO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mereo Biopharma Group Plc(MREO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction